Santaris Advances Two Hypercholesterolemia Rx Candidates; One Poised to Enter Clinical Trials in 2010

The company also reported its third-quarter financial results, posting a 31 percent drop in its loss amid lower research and development spending.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.